Sensitivity of KRAS-Mutated Non-Small Cell Lung Cancer to a Combination of MEK Kinase Inhibitor (Trametinib) and Autophagy Inhibitor (Hydroxychloroquine) in a Tissue Explant Model. (2026). Voprosy Onkologii, 72(1), OF-2403. https://doi.org/10.37469/0507-3758-2026-72-1-OF-2403